Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai Joins TB Discovery Initiative | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Eisai Joins TB Discovery Initiative

Aims to develop one-month treatment therapy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai has joined the Tuberculosis Drug Accelerator (TBDA) partnership, a new initiative that aims to speed the discovery of essential new treatments for tuberculosis (TB). The TBDA partnership, launched in June 2012 through a collaboration between several pharmaceutical companies, research institutions and with support from the Bill & Melinda Gates Foundation, targets the discovery of new TB drugs by working together on early-stage research. The long-term goal of the partnership is to create a new TB drug combination that has the potential to cure patients in one month only, compared to the six months of treatment required by existing treatments.
 
Eisai will provide targeted sections of its compound libraries for screening against TB and share identified and confirmed hits with other TBDA partners. Eisai will also work with other partners to facilitate the development of new TB therapies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics